207 related articles for article (PubMed ID: 18194405)
1. Using cost-effectiveness analysis to sharpen formulary decision-making: the example of tiotropium at the Veterans Affairs health care system.
Onukwugha E; Mullins CD; DeLisle S
Value Health; 2008; 11(5):980-8. PubMed ID: 18194405
[TBL] [Abstract][Full Text] [Related]
2. [Economic value of tiotropium in the treatment of chronic obstructive pulmonary disease].
Schramm W; Haake D; Brandt A
Praxis (Bern 1994); 2005 Nov; 94(46):1803-10. PubMed ID: 16329401
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore.
Lee KH; Phua J; Lim TK
Respir Med; 2006 Dec; 100(12):2190-6. PubMed ID: 16635566
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease.
Oba Y
Mayo Clin Proc; 2007 May; 82(5):575-82. PubMed ID: 17493425
[TBL] [Abstract][Full Text] [Related]
5. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
Oostenbrink JB; Rutten-van Mölken MP; Monz BU; FitzGerald JM
Value Health; 2005; 8(1):32-46. PubMed ID: 15841892
[TBL] [Abstract][Full Text] [Related]
6. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain.
Rutten-van Mölken MP; Oostenbrink JB; Miravitlles M; Monz BU
Eur J Health Econ; 2007 Jun; 8(2):123-35. PubMed ID: 17370096
[TBL] [Abstract][Full Text] [Related]
7. Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease.
Dalal AA; Roberts MH; Petersen HV; Blanchette CM; Mapel DW
Int J Chron Obstruct Pulmon Dis; 2010 Dec; 6():13-22. PubMed ID: 21311689
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD.
Sun SX; Marynchenko M; Banerjee R; Cheng D; Mocarski M; Yin D; Yu AP; Wu EQ
J Med Econ; 2011; 14(6):805-15. PubMed ID: 21992217
[TBL] [Abstract][Full Text] [Related]
9. Comparative health-care cost advantage of ipratropium over tiotropium in COPD patients.
Dormuth CR; Yamaguchi J; Wilmer B; Hosick D; Stürmer T; Carney G
Value Health; 2012; 15(2):269-76. PubMed ID: 22433758
[TBL] [Abstract][Full Text] [Related]
10. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease.
Oostenbrink JB; Rutten-van Mölken MP; Al MJ; Van Noord JA; Vincken W
Eur Respir J; 2004 Feb; 23(2):241-9. PubMed ID: 14979498
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial.
Hoogendoorn M; Al MJ; Beeh KM; Bowles D; Graf von der Schulenburg JM; Lungershausen J; Monz BU; Schmidt H; Vogelmeier C; Rutten-van Mölken MP
Eur Respir J; 2013 Mar; 41(3):556-64. PubMed ID: 22700844
[TBL] [Abstract][Full Text] [Related]
12. [Cost-effectiveness analysis of tiotropium compared to ipratropium and salmeterol].
García Ruiz AJ; Leiva Fernández F; Martos Crespo F
Arch Bronconeumol; 2005 May; 41(5):242-8. PubMed ID: 15919004
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries.
Nielsen R; Kankaanranta H; Bjermer L; Lange P; Arnetorp S; Hedegaard M; Stenling A; Mittmann N
Respir Med; 2013 Nov; 107(11):1709-21. PubMed ID: 23856511
[TBL] [Abstract][Full Text] [Related]
14. Tiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions.
Neyt M; Devriese S; Thiry N; Van den Bruel A
BMC Pulm Med; 2010 Sep; 10():47. PubMed ID: 20843311
[TBL] [Abstract][Full Text] [Related]
15. Which long-acting bronchodilator is most cost-effective for the treatment of COPD?
Hoogendoorn M; Kappelhoff BS; Overbeek JA; Wouters EF; Rutten-van Mölken MP
Neth J Med; 2012 Oct; 70(8):357-64. PubMed ID: 23065983
[TBL] [Abstract][Full Text] [Related]
16. Tiotropium: a potential replacement for ipratropium in patients with COPD.
Shukla VK
Issues Emerg Health Technol; 2002 Jul; (35):1-4. PubMed ID: 12195603
[TBL] [Abstract][Full Text] [Related]
17. Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium.
Hettle R; Wouters H; Ayres J; Gani R; Kelly S; Lion M; Decramer M
Respir Med; 2012 Dec; 106(12):1722-33. PubMed ID: 23040833
[TBL] [Abstract][Full Text] [Related]
18. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD.
Gani R; Griffin J; Kelly S; Rutten-van Mölken M
Prim Care Respir J; 2010 Mar; 19(1):68-74. PubMed ID: 20094687
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of tiotropium and ipratropium in prevention of hospital readmission for COPD: a population-based cohort study.
Kawasumi Y; Paterson MJ; Morrow RL; Miller TA; Bassett K; Wright JM; Dormuth CR
Clin Ther; 2013 Apr; 35(4):523-531.e1. PubMed ID: 23490290
[TBL] [Abstract][Full Text] [Related]
20. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease.
Lee TA; Wilke C; Joo M; Stroupe KT; Krishnan JA; Schumock GT; Pickard AS
Arch Intern Med; 2009 Aug; 169(15):1403-10. PubMed ID: 19667304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
